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The effect of MElatonin on Depressive
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Abstract
Background: Depression following acute coronary syndrome (ACS) constitutes a serious and debilitating problem.
Approximately one in five patients will develop significant depression following ACS and less severe depressive
symptoms are even more frequent. Furthermore, anxiety symptoms and sleep-wake disturbances are frequent.
The objective of the MEDACIS trial is to investigate whether prophylactic treatment with melatonin has a
preventive effect on depression, depressive and anxiety symptoms, sleep, and circadian disturbances following ACS.
Methods/design: “The effect of MElatonin and Depressive symptoms, Anxiety, CIrcadian and Sleep disturbances in
patients after acute coronary syndrome” trial (MEDACIS) is a multicenter, double-blinded, placebo-controlled,
randomized clinical trial. A total of 240 patients with ACS and no depressive symptoms will be included in the trial
for treatment with either 25 mg melatonin or placebo for a 12-week period. Development and severity of
depressive symptoms will be evaluated using Major Depression Inventory every 2 weeks with the purpose of
investigating the potential preventive effect of melatonin on depressive symptoms.
Discussion: Previously, only selective serotonin reuptake inhibitors (SSRIs) have been investigated in a primary
preventive setup in patients following ACS. However, SSRIs are associated with several side effects. An ideal
intervention would constitute the highest degree of prevention of depressive symptoms with the lowest risk of
side effects. In this regard, melatonin may have advantages due to its low toxicity as well as its proven anxiolytic
and hypnotic effects.
Trial registration: ClinicalTrials.gov, Identifier: NCT02451293. Registered on 12 May 2015. EudraCT nr. 2015-002116-32.
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Background
By the year 2030 it has been anticipated that depressive
disorder and ischemic heart disease will be the first and
second leading causes of disability in developed nations,
respectively [1]. Worldwide, an estimated 7 million
people or more each year suffer from myocardial infarc-
tion (MI) [2]. In Denmark in 2011, the incidence rate of
acute myocardial infarction was 553 cases/100,000
person-years, a prevalence of 4570 cases/100,000 per-
sons, and a mortality of 123 cases/100,000 persons [3].
The prevalence of major depressive disorder following
acute coronary syndrome (ACS) has been reported to be
approximately 19.8% ((CI) 19.1% to 20.6%) assessed by
structured clinical interviews [4]. However, the preva-
lence varies according to the tool used to evaluate
depression [4–6], e.g., if the most frequently used self-
report instrument, the Beck Depression Inventory (BDI),
is used the prevalence is 31.1% ((CI) 29.2% to 33.0%) [4].
However, a prevalence as high as 50.5% has been re-
ported with other questionnaires [5].
Depression following ACS has been associated with a
2.25 ((odds ratio), CI 1.73 to 2.93) increase in all-cause
mortality, and a 2.71 ((odds ratio), CI 1.68 to 4.36) in-
crease in cardiac mortality within 24 months of the pri-
mary event [7]. Depression was recently categorized by
the American Heart Association (AHA) as an independ-
ent risk factor for adverse medical outcomes in patients
after ACS [6]. Furthermore, the AHA has made recom-
mendations for implementing screening for depression
in the post-MI period [8].
Anxiety symptoms following ACS have not received as
much attention as post-ACS depression [9]. A mix of
both depressive and anxiety symptoms tend to coexist in
patients following ACS [10] and they are found in up to
90% of depressed patients following MI [11]. The preva-
lence of anxiety symptoms varies from 24 to 37% among
hospitalized MI patients [12, 13], and has been found to
be associated with a 1.47-fold ((odds ratio), CI 1.02 to
2.13) increase in all-cause mortality [14]. However, a
more recent meta-analysis could not confirm [15] this in
post-ACS patients and the relationship was thought to
be attenuated by comorbid depression. Anxiety symp-
toms have been shown to reduce heart rate variability
[16], activate the hypothalamic-pituitary-adrenal axis
[17], and enhance fibrin turnover [18]. Furthermore,
anxiety is an independent predictor of cardiac events
following MI [11, 19].
Sleep disturbances are prevalent in cardiac patients
[20] and sleep disturbances are an integral part of both
depression and anxiety symptoms [21]. In fact, in rela-
tion to the pathophysiology of depressive disorders, sleep
and sleep-wake disturbances have been identified as two
of the most important contributing factors [22]. The
prevalence of sleep disturbances in ACS patients has not
received sufficient attention [20], and the primary focus
of the medical literature has been on sleep apnea, be-
cause of the known relationship between sleep-
disordered breathing and cardiovascular morbidity [23].
This lack of relevant medical literature is disturbing, es-
pecially seen in the light of poor sleep having been
shown to be associated with a 2.5-fold increased risk of
recurrent cardiac events in women after ACS [24].
There exists a complex relationship between depression,
sleep and circadian disturbances [25], and residual sleep
disturbances may remain despite treatment of depression
[26]. Furthermore, cognitive behavioural therapy (CBT)
and pharmacotherapy have been shown to be equally ef-
fective in treating sleep disturbances after remission from
depression [26]. Both psychological and pharmacological
interventions could potentially be warranted in patients
suffering from both medical illness and depression [27].
As oppose to antidepressants, psychotherapy has been
shown to have a small but significant effect in the preven-
tion of depression after stroke [28]. However, a limitation
of psychological interventions is that the therapist and pa-
tient cannot be blinded to allocation which increases the
risk of bias. An intervention where blinding is possible
and which can target both the depression and the anxiety
as well as the circadian and sleep disturbances in patients
after ACS would be of clinical interest.
One possible pharmacological intervention investigated
in the current trial could be the endogenous hormone
melatonin (ATC: N05CH01). Melatonin is secreted from
the pineal gland in a circadian pattern, controlled by the
endogenous circadian pacemaker in the suprachiasmatic
nuclei [29]. The primary function of melatonin is to
synchronize the circadian rhythm of the body [29].
However, melatonin is a multipotent hormone and affects
multiple processes in the human body [30–36] (Fig. 1). It
has been shown to prevent depressive symptoms over a 3-
month period in patients with breast cancer [37]. In the
Fig. 1 MElatonin on Depressive symptoms, Anxiety, CIrcadian and
Sleep disturbances (MEDACIS) trial. Potential effects of exogenous
melatonin intervention
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same population, it was shown to improve sleep quantity
and quality both during a 2-week and a longer-term
period (3 months) [38, 39]. Meta-analyses have shown
melatonin to be effective in the treatment of primary sleep
disorder [40]; however, the effect in secondary sleep
disorders is limited [41]. In a perioperative setting, mela-
tonin treatment has been shown to have an anxiolytic
effect [42]. Choosing the ideal dose of melatonin regarding
its antidepressant effect is difficult as no ideal dose-
response studies have been carried out on this indication.
Typically, melatonin is administered in under 10-mg doses
[43] which is the dose used for treatment of insomnia in
patients aged over 55 years [44]. The melatonin agonist
agomelatine is on the market for the treatment of depres-
sion, and choosing an equipotent dose of melatonin to this
agonist has been suggested [30]. The pharmacodynamics
and pharmacokinetics of agomelatine and melatonin are
similar [30] and the induction dose of agomelatine is
25 mg. A dose of 25 mg was chosen in the current trial as
a balance between the primary prophylaxis (treatment
before incident disease) design and the nontoxic profile of
melatonin [40, 41, 45].
Aim
The primary aim of the current study is to investigate a
possible prophylactic antidepressant effect of melatonin
in patients following ACS. Secondary aims will be to in-
vestigate whether melatonin will have effect on anxiety
symptoms, sleep disturbances and circadian rhythm.
Methods/design
The MEDACIS trial is a multicenter, double-blinded,
placebo-controlled, randomized clinical trial investigating
the effect of 25 mg exogenous melatonin (intervention
group) against placebo (control group) and the study is
designed as a parallel-group trial. The participants will be
followed for a period of 12 weeks during the trial and
assessed on outcomes continuously throughout the period
(Figs. 2 and 3).
Study setting
The study is performed in Region Zealand of Denmark,
and patients will be recruited from three cardiology
departments (Department of Cardiology at Holbaek
Hospital, Roskilde Hospital and Koege Hospital in
Fig. 2 MElatonin on Depressive symptoms, Anxiety, CIrcadian and Sleep disturbances (MEDACIS) CONSORT diagram. Consolidated Standards of
Reporting Trials (CONSORT) diagram for the MEDACIS trial
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Region Zealand, Denmark) within the region. Roskilde
Department of Cardiology has the function of performing
coronary angiography (CAG) and, if necessary, percutan-
eous coronary intervention (PCI) in the region. A subset of
the patients will have their CAG and PCI performed at the
Department of Cardiology, Rigshospitalet, Copenhagen,
Denmark, but will be admitted to their regional hospital
afterwards. A list of recruiting sites can be found at
www.clinicaltrial.gov with Identifier NCT02451293.
Eligibility criteria
Inclusion criteria
1. Patients should be admitted to a coronary care unit
for ACS [46], and should be enrolled at the latest
4 weeks after the primary ACS
2. Participants should be aged 18 years or older
3. No sign of current depression on the Major
Depression Inventory (MDI) used as a diagnostic
tool at the point of enrollment
4. Participants must sign an Informed Consent Form.
5. Premenopausal women (defined as no menstruation
during the last 12 months) should have a negative
pregnancy test. Furthermore, women of
reproductive age should use reliable birth control
(intrauterine devices, hormonal contraceptives
including oral pills, patches, vaginal rings, and
injections) during the entire trial period
Exclusion criteria
1. Known allergic reaction to melatonin
2. Ongoing or previous pharmacologically treated
depression or bipolar disorder
3. No dementia as determined by a Mini Mental State
Examination (MMSE) score <24 is allowed
4. At the point of inclusion no participation in
other pharmacological intervention trials is
allowed
5. No participants with a diagnosis of Rotor syndrome
or Dubin-Johnson syndrome, epilepsy, sleep apnea
syndrome, systemic lupus erythematosus (SLE),
rheumatoid arthritis (RA) or multiple sclerosis are
allowed
6. Severe liver disease, defined as transaminases above
three times normal levels, and severe kidney disease
defined as an eGRF under 40 ml/min
7. Chronic hypnotic treatment previous to the ACS
8. Known sleep disorder (e.g., insomnia, restless legs, etc.)
9. Work involving nightshifts
10.Daily alcohol consumption above 5 units of alcohol
(1 unit = 12 g alcohol)
11.Predictable poor compliance (not speaking fluent
Danish)
12.Pregnant or breastfeeding women
13.Severe, life-threatening medical condition that im-
plies that the patient cannot participate in the study
course (e.g., cancer, stroke)
14.Indication for coronary artery bypass graft (CABG)
Interventions
Patients will receive either 25 mg exogenous melatonin
(intervention group) or matching placebo (control group)
in an orally administered pill. Regarding the active sub-
stance each pill will contain 12.5 mg melatonin, and the
placebo pill will be comparable to study medication except
for the active substance. The medication will be packaged
in blister packs consisting of 30 pills in each, and a total of
Fig. 3 MElatonin on Depressive symptoms, Anxiety, CIrcadian and Sleep disturbances (MEDACIS) Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) figure. SPIRIT figure for the MEDACIS trial
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seven blister packages will be packaged in a cardboard box
(total of 210 pills). Patients will be instructed to take two
pills (daily dose of 25 mg active substance) approximately
1 h before bedtime during the entire length of the study
(12 weeks). Medicine compliance will be investigated at
weeks 2 and 12 at clinical visits. All study medication will
be produced by PharmaNord Aps. (Vejle, Denmark) in
accordance with Good Manufacturing Procedure (GMP).
The study medication will be shipped to the Region Zealand
Hospital Pharmacy which will handle the randomization
process.
If a participant withdraws their consent, they will leave
the study. In the unlikely event that a female participant
should become pregnant despite using reliable birth con-
trol, she will leave the study. Patients who have a recur-
rence of ACS during the study will be withdrawn from
the study. In case of severe medical emergency (e.g.,
stroke or severe sepsis) requiring emergency surgery,
stay in an intensive care unit, or more than 1 week of
hospitalization will result in exclusion from the study.
Diagnosis of a cancer during the study period will also
result in withdrawal from the study. No further data will
be collected from patients after leaving. However, previ-
ously collected data will be part of the final data analysis.
No change in dose of study medication will be possible
during the trial.
A medicine compliance of a minimum of 75% (pill
count) at the clinical visits at weeks 2 and 12 are re-
quired. If the patients do not comply with these de-
mands at either visit, they will be excluded from the
study. Exclusion from the study entails stopping the
study medication, and patient’s data will not be part of a
per-protocol analysis. In case of medicine compliance at
the first clinical visit, the data collected until this point
will be part of a per-protocol analysis.
If a patient is diagnosed with a moderate-to-severe
depression on the MDI during the study, they will be re-
ferred to a psychiatrist in training attached to the study
(who is blinded to the allocated treatment). The psych-
iatrist in training will perform a structured clinical inter-
view (Hamilton Depression Scale) with the purpose of
diagnosing depression and its severity according to the
International Classification of Diseases, version 10 (ICD-
10) criteria. Patients with a moderate-or-severe depressive
episode according to the Hamilton Depression Scale and
clinical assessment will be withdrawn from the study and
offered open treatment for depression via the patient’s
general practitioner (GP). All outcome data collected until
the eventual termination in the study will be part of the
final analysis. If the patient is diagnosed with a mild de-
pression on the MDI, they will be allowed to continue in
the study. The patient will be monitored using the MDI
and phone calls according to the study protocol. In case of
symptom progression on the MDI into moderate to severe
depression, the participant will be referred to the psych-
iatrist in training as described above.
Patients will be contacted by phone seven times (every
2 weeks) during the trial to assure compliance and to pro-
mote their retention during follow-up. The patients will
be reminded to fill in the relevant study questionnaires,
reminded to take study medication, and monitored for oc-
currence of any adverse reactions, or changes in other
medication since last contact with study investigators.
The participants are allowed to participate in all
offered concomitant care at their regional cardiology
department (e.g., cardiac rehabilitation). Startup of any
medical antidepressant treatment in the trial period is
prohibited and will lead to exclusion from the trial.
Outcomes
Primary outcome
The MDI is a self-rating scale with 12 questions. It has
been extensively used in a Danish population [47] and is
also thoroughly validated [48]. The questions cover the
ten ICD-10 symptoms for depression, which are identi-
cal to the Diagnostic and Statistical Manual of Mental
Disorders, 4th edition (DSM-IV) major depression diag-
nostic criteria except for one symptom, low self-esteem
(question 4), which in DSM-IV is incorporated into a
question about guilt (question 5).
The MDI holds a double function. It can be used as a
diagnostic tool which, via an algorithm, can be trans-
formed into the DSM-IV or ICD-10 categories of “mild,”
“moderate,” or “severe” depression. The tool has been
found to have satisfactory sensitivity and specificity with
regard to the diagnosis of depression according to both
the ICD-10 and DSM-IV [49]. The MDI can also be used
as a rating scale, which can grade the severity of depres-
sion and this has been found to have an acceptable correl-
ation with the Hamilton Depression Scale (HAM-D) [48].
Primary outcome Exploratory outcomes
Major Depression
Inventory (MDI)
Pattern of dropouts and withdrawals
from the study
Safety, side effect and compliance
to study medication
Anxiety and depression measured by
the Hospital Anxiety and Depression
Scale (HADS)
Sleep and circadian outcomes measured
by actigraphy
Subjective sleep quality measured by the
Pittsburgh Sleep Quality Index (PSQI)
Sleep diary
Sleep, pain, anxiety, fatigue and general
wellbeing measured by visual analog
scales (VAS)
Blood samples – Circadian clock gene analysis
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For the purpose of the current study, the MDI will be
used as a diagnostic tool at baseline with regard to the
eligibility (inclusion/exclusion criteria) of the participants.
Mild depression excludes participation and, as a diagnos-
tic tool, mild depression is the presence of two core symp-
toms and two accompanying symptoms of depression.
During the study, the MDI will be used as a rating scale to
evaluate the severity and development of depressive symp-
toms. As a rating scale, a total MDI score (0–50 points) of
21 to 25 points corresponds to a mild depression, of 26 to
30 a moderate depression and above 31 points constitutes
a severe depression. Incident depressive symptoms, de-
fined as MDI score ≥21 any time after baseline MDI, is
the primary outcome assessed using the MDI as a rating
scale. Timing of outcome assessment can be seen in the
SPIRIT figure (Fig. 3).
Exploratory outcomes
The pattern of participants leaving the study before
completion of the 12-week period will be investigated.
The different reasons for leaving the study (e.g., with-
drawal of consent, medicine compliance, recurrent ACS,
etc.) will be compared between the two groups. Further-
more, the timing of dropout between the two groups will
be compared.
Safety and potential side effects will be closely monitored
during the entire trial and reported in the proceeding publi-
cation. For specifics, see the “Harms and adverse events”
section.
The Hospital Anxiety and Depression Scale (HADS)
was originally developed by Zigmond and Snaith in 1978
[50] with the purpose of developing an easy-to-use tool
for screening for mood disorders in a hospital setting. In a
cardiac setting HADS-D has been shown to have adequate
internal consistency, reliability and construct validity [51].
Actigraphy is a noninvasive method used to objectively
evaluate a patient’s sleep and circadian rhythm. An acti-
graph (Octagonal Basic Motionlogger, Ambulatory Moni-
toring Inc., Ardsley, NY, USA), which is a wrist-worn
minicomputer, will be mounted on the participant’s non-
dominant wrist at enrollment and worn for 2–3 weeks until
the first clinical visit. Actigraphy has been shown to have a
high validity and accuracy compared to polysomnography
(PSG), the “gold standard” of sleep evaluation [52]. Actigra-
phy has been used extensively in patients undergoing sur-
gery [53] and in cancer patients [54] but has not been
investigated thoroughly in post-ACS patients [20].
Subjective sleep outcomes will be evaluated using a
sleep diary, visual analog scales (VAS), and the Pittsburgh
Sleep Quality Index (PSQI). A sleep diary is the patient’s
own account of sleep data, and the patient is asked to fill
in a diary page each morning after awakening. Visual ana-
log scales regarding sleep will also be assessed on the scale
ranging from “best conceivable sleep” at 0 mm to “worst
conceivable sleep” at 100 mm. Furthermore, patients will
fill out VAS on general wellbeing, fatigue, pain and
anxiety. Lastly, the patients will fill out the PSQI, which
assesses sleep quality during the prior 4 weeks and has a
clinically established cutoff of ≥5 as being a poor sleeper
and ≥8 as having sleep problems needing treatment [55].
Blood analysis will analyze for circadian genotype PER
3 which has a variable number tandem repeat (VNTR)
polymorphisms (unique to primates) that consist of ei-
ther a 4- or 5-U repeated coding region. PER 3 has been
associated with sleep disorders [56], affective disorders
[57] and reduced cognitive function in relation to sleep
deprivation [58]. We will investigate a possible relation-
ship between circadian genotype (clock genes), sleep-
wake cycle, and depressive symptoms following ACS.
Participant timeline
A diagnosis of ACS is made by the attending physician
according to relevant guidelines. Eligible participants
(according to the inclusion and exclusion criteria) will be
informed about the study by the clinical investigating
team, and if possible, a later inclusion meeting will be
planned. Hereby, the potential participants will receive ad-
equate time to consider participation and the possibility of
bringing an assessor. The participant will be presented to
the study during their initial admission for ACS or at a
later joint meeting during cardiac rehabilitation. A partici-
pant should be included within 4 weeks of their ACS. The
participants’ flow through the study can be seen in the
CONSORT flow diagram (Fig. 2) and the timing of out-
come measurement in the SPIRIT figure (Fig. 3).
Sample size
Sample size is calculated on the basis of a conservative as-
sumption that 31% of patients following ACS will develop
depressive symptoms [4] which we assume can be reduced
to 15.5% by melatonin treatment. Power calculation is
based on two-sided test and, with a power of 0.80 and a
significance level of 5% (α = 0.05), the required sample size
in each group is 116. There are no interim efficacy ana-
lyses planned. The patients will be randomized in blocks
of 6 and, therefore, the study will proceed until 120 pa-
tients have been enrolled in each arm.
Recruitment
To assure adequate recruitment to the trial, the study
will take place at three departments simultaneously.
Recruitment from three departments should provide
sufficient participants to ensure the target sample size.
In case of insufficient recruitment further recruiting
centers will be sought and included if possible.
Madsen et al. Trials  (2017) 18:81 Page 6 of 11
Assignment of interventions
The randomization process will be handled by the re-
gional pharmacy in Region Zealand, Denmark. The
randomization list/sequence will be made before the
study start by using a dedicated online software (http://
www.randomization.com/) by the regional pharmacy.
Block randomization, in blocks of 6, will be used. In
each block, half the patients will receive the intervention
drug (melatonin 25 mg), and the other half the placebo.
The randomization list will be kept at the regional phar-
macy and will not be available to the investigators
recruiting the participants.
Allocation concealment consists of two sets of coded en-
velopes (an opaque, sealed envelope for each patient, con-
taining the randomization code for each patient) which will
be produced by the Regional Pharmacy of Region Zealand.
The two envelopes will be sent to Koege Hospital (sponsor’s
center) and stored there; one in the patients Case Report
Form (CRF), and the other in the Trial Master File (TMF).
In this way, the blinding will be conserved for both the
sponsor/investigator and other investigators who enroll and
assign treatments to the participants.
After assignment into the trial, the trial participant, inves-
tigators, care providers, outcome assessors and data ana-
lysts will be blinded to the allocated treatment. In case of a
suspected unexpected serious adverse reaction (SUSAR),
unblinding can be performed by the investigators using the
coded envelopes available in the patient’s CRF.
Data collection
Data are collected in participant-specific Case Report
Forms (CRFs) and will be stored for a 5-year period after
study termination. As standard, an electronic CRF
(eCRF) will be used to collect all study data from each
participant throughout the study. The eCRF is created
using the online platform Easytrial.net (Easytrial ApS,
Glostrup, Denmark) which serves as the electronic data
storage of the clinical trial. The individual questionnaires
are sent to the individual participants via email with a
unique generated link. In case a participant is noncom-
pliant with the electronic setup (i.e., no Internet connec-
tion), they will fill out study questionnaires in paper
format and the data will be transferred manually to the
online study database. At the point of inclusion, baseline
demographics will be collected from the patient and the
patient record.
As previously described, phone calls and electronic (e.g.,
email) reminders will be sent out to assure participant re-
tention and reduce loss to follow-up. No additional data
are to be collected if a participant discontinues study
medication or in other ways does not comply with the
intervention protocols.
Using the eCRF implies that answered questionnaires
are source data and are transferred directly to the
electronic database upon completion. The sleep diary
and the VAS administered for the initial 2 weeks are in
paper format, and will later be transferred to the elec-
tronic database using double data entry. The study will
be performed in accordance with Good Clinical Practice
(GCP) and monitored by the GCP Unit from the Univer-
sity of Copenhagen. After completion of the trial the
sponsor/investigator (first author) will have access to the
final trial dataset.
Statistics
Descriptive data on baseline characteristics and results
will be presented as mean, SD, and n and presented in
tabular form. Distribution of data will be tested by using
data plots and by visually assessing data, and potentially
continuous variables will be visualized in a matrix plot.
Appropriate statistical tests will be used accordingly de-
pending on distribution. Log transformation will be ap-
plied if applicable.
Our null hypothesis is that there will be no difference
in the number of participants developing depressive
symptoms (defined as a MDI score ≥21) throughout the
study period between the melatonin and the placebo
group. The hypothesis is assessed using Fisher’s exact
test and/or the chi-squared test.
For the primary outcome analysis, a linear mixed model
will be applied. The effect of age, gender, comorbidity and
cardiac risk factors will be assessed by marginal analysis.
Results will be assessed through an analysis on complete
data generated using multiple imputation.
As a secondary analysis, the cumulative incidence of de-
pressive symptoms will be plotted for the two groups and
compared using the log-rank test assuming the absence of
competing risks. Incidence of depressive symptoms (MDI
score ≥21) will be analyzed using the Cox proportional
hazards regression, including analysis of effects of age,
gender, comorbidity and cardiac risk factors at baseline.
A principle analysis will be performed according to the
intention-to-treat principle (ITT). The intention-to-treat
population is defined as every patient randomized into
the trial. A per-protocol analysis will also be performed.
A per-protocol participant is defined as a patient who
has taken medication in accordance with the protocol
(at least 75%) for the first 14 days (until the follow-up
visit). In cases of noncompliance with the medication
before the follow-up visit (i.e., exclusion from the study),
another patient will be enrolled to make up for the lost
patient. Finally, a standard sensitivity analysis will be
performed on the per-protocol patient population.
For secondary/exploratory outcomes, intergroup com-
parison for anxiety and depression (HADS) will be made
at baseline, 2 and 12 weeks. The data originating from the
actigraphy measurement will be presented as sleep and
circadian outcomes. The sleep outcomes will be divided
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into units of 3 days as recommended [59], and descriptive
data will be presented for the entire 2-week measuring
period. Sleep diary and VAS measured each day simultan-
eously with actigraphy will be termed short-term sleep/
VAS outcomes. Sleep diary and VAS measured afterwards
every 2 weeks will be termed long-term sleep/VAS out-
comes. Intergroup comparisons of PSQI data will be made
at baseline, 4, 8 and 12 weeks. For all continuous data, in-
tergroup comparisons will be done using an unpaired Stu-
dent t test or Mann-Whitney’s test depending on
distribution of data. For analysis of the correlation be-
tween circadian genotype, depressive symptoms and sleep,
a logistic regression analysis will be used.
A P value < 0.05 will be considered statistically signifi-
cant. For exploratory outcomes all analysis will be pre-
sented and no statistical correction for multiple testing
will be applied [60]. No interim analysis is planned for
the study. A priori, no subgroup analysis is planned [61].
The statistical analysis plan has been consulted with an
external independent statistician. The analysis of data
will, upon study completion, be handled and performed
by the first author, and the process will be aided by the
external study statistician. An appropriate statistical soft-
ware package will be applied for the statistical analysis.
Harms and adverse events
To monitor harms and adverse events two systems will
be employed in the current trial. Firstly, at each clinical
visit and during each phone call the patient will be inter-
viewed regarding possible side effects according to the
summary of product characteristics which contains a list
of known side effects. Furthermore, an open-ended
question regarding side effects will be asked to try to de-
tect any unexpected side effects.
Secondly, the “udvalg for klinisk undersøgelser” (UKU)
manual will be used to monitor harms. The UKU has
been developed for monitoring the side effects of psy-
chotropic drugs and has been validated in several Nordic
countries [62]. A self-rating version of the UKU side ef-
fect rating scale (UKU-SERS-Pat) has been developed
and validated against the clinician-administered version
(UKU-SERS-Clin) [63]. The UKU-SERS-Clin is time-
consuming which may hinder its usage in clinical prac-
tice with the possibility of overlooking severe side effects
that may be avoided. Furthermore, development of a
patient-administered version may gain more information
about side effects as patients and clinicians perceive
them differently [63]. Overall, the intercorrelation be-
tween the patient- and clinician-administered UKU was
shown to be statistically significant [63]. When working
with antidepressants, the UKU-SERS paper [62] states
that neurological symptoms may be omitted from the
evaluation, and this will be done in the current study. In
the current clinical trial, the UKU-SERS-Pat will be
administered at the clinical visits and in the ambulatory
setting at the point in the trial when the clinical status
(MDI) is being evaluated.
Ethics, monitoring and reporting
The study will be performed in agreement with the
Helsinki II Declaration and law 593 of 2011 pertaining
to the Scientific Ethics Committee System. The project
is registered at www.ClinicalTrials.gov (NCT02451293)
as recommended by the International Committee of
Medical Journal Editors (ICMJE). The Good Clinical
Practice Unit at Copenhagen University will oversee the
trial and conduct monitoring visits of the trial periodic-
ally. The protocol has followed the SPIRIT guidelines
(Additional file 1), and the manuscript will follow the
CONSORT Statement [64]. In accordance with CON-
SORT guidelines, both positive, neutral and negative
findings will be published [64]. In case of important
modifications to the protocol (e.g., changes in eligibility
criteria), trial investigators will be informed and the
www.ClinicalTrials.gov registration updated. Authorship
guidelines put forth by the ICMJE will be applied for all
publications originating from the current trial.
Discussion
The current manuscript describes a protocol for a pri-
mary prophylactic study targeting nondepressed patients
following ACS. To the best of our knowledge, we are the
first to investigate melatonin’s antidepressant, anxiolytic
and hypnotic effects in this population.
The predominant focus of previous trials has been the
treatment of depression in patients following ACS. A recent
Danish study showed that 20% of patients following ACS
have an incident depression and 67% of medical antidepres-
sant treatment is made up of selective serotonin reuptake
inhibitor (SSRIs) [65]. This is coherent with a systematic
review describing the increased use of antidepressants
(predominantly SSRIs) during the last three decades [66].
Awareness and treatment of depression following ACS has
risen during the last decades; however, not much attention
has been focused on preventive interventions.
We know of only one previous trial using a similar pri-
mary preventive strategy [67, 68], which showed an effect
of prophylactic treatment with escitalopram (Cipralex)
[67]. However, treating patients with a SSRI (SSRI before
the onset of depression is not without risk. Treatment with
SSRIs have been shown to be associated with sleep distur-
bances, sexual disturbances and arrhythmias [30]. Recently,
specific concerns regarding the cardiotoxicity of citalopram
(also escitalopram) have been raised [69]. There exists a
dose-response relationship between citalopram and the
prolonged QT interval syndrome which, in some cases,
leads to sudden cardiac death. Furthermore, patients with
a previous cardiac event (e.g., MI) constitute a high-risk
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population [69]. The DECARD trial [67] has, in light of
this, been criticized for the unnecessary potential harm as-
sociated with SSRI treatment caused to nondepressed pa-
tients with a previous cardiac event. The premise of
preventing the development of depressive symptoms in the
specific population is, however, controversial. Any such
intervention should, of course, have the highest degree of
benefit and the lowest incidence of side effects.
Melatonin was chosen for the current trial in light of
these considerations, and on the basis of positive results
from a previous similar trial in women with breast cancer
[37]. It should be mentioned that the study did not include
the planned number of patients due to slow recruitment;
however, the effect of melatonin was greater than assumed
a priori [37]. Melatonin has repeatedly been shown to have
sleep-improving effects in women with breast cancer [38,
70, 71]. As melatonin is widely safe and nontoxic, even
when given to animals and humans in high exogenous
doses over extended time periods [35, 45, 72], it would be a
good candidate for a prophylactic setup. Exogenous mela-
tonin has been investigated in multiple clinical trials and
with multiple outcomes [31, 43]. Melatonin has recently
been reviewed as treatment for clinical depression in both
prophylactic and treatment setups [43], where no signifi-
cant antidepressant effect of melatonin was shown in either
setting. However, it was concluded that the included studies
were heterogonous and of low quality, and that further
properly dimensioned trials will be needed before any con-
clusion can be made. The review does not include the pre-
viously mentioned positive prophylactic melatonin trial
performed in breast cancer patients [37]. Furthermore, the
included trials have used a low dose of melatonin, typically
under 10 mg [43] which is the dose used for treatment of
insomnia in patients aged over 55 years [44]. It has been ar-
gued by Cardinali et al. that the antidepressant potential of
melatonin cannot be determined before trials using equiva-
lent doses of melatonin compared to other melatonergic
agonists [30] have been performed. This would constitute
trials of 25–100 mg melatonin, and taking into consider-
ation the prophylactic setup of our trial, we chose a dose of
25 mg. In a dose-response study, a dose of 25 mg Valdoxan
(agomelatine, a melatonin agonist) was found to be most
effective as an antidepressant [73], and 25 mg is typically
the recommended induction dose for Valdoxan in treat-
ment of major depressive disorders. To the best of our
knowledge, a similar dose-response trial does not exist for
melatonin in relation to its antidepressant effect. Twenty-
five milligrams is, therefore, arbitrarily chosen, but it is
never-the-less the dose chosen in light of the dose-response
antidepressant effects seen in melatonin agonists.
Besides the positive effect on depressive symptoms,
melatonin may also be used to treat anxiety, sleep and
circadian disturbances. Melatonin has been recom-
mended as the first-line treatment of patients aged over
55 years suffering from insomnia, parasomnia and circa-
dian rhythm sleep disorders [44]. Exogenous melatonin
administered in the perioperative period has recently
been reviewed [31], showing a significant anxiolytic and
analgesic effect. Overall, melatonin is a relevant and safe
intervention to be tested for potentially beneficial effects
against depressive symptoms, anxiety and sleep and cir-
cadian disturbances in patients following ACS.
Status of the trial
The study gained all relevant approvals during the end of
2015, and permission to initiate the trial was gained on 20
January 2016. The trial was initiated firstly at the
Departments of Cardiology at Zealand University Hospital
(Koege), followed by Zealand University Hospital (Roskilde)
and lastly Holbaek Hospital.
The trial has at this point included 150 out of 240
patients.
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